EU seeks 10 million AstraZeneca vaccines from India to meet shortfall: Report

The EU wants the doses from Serum, the world's largest vaccine maker, to offset supply shortfalls from AstraZeneca's European plants and speed up the bloc's vaccine roll-out.

Reuters
April 01, 2021 / 07:09 PM IST

Representative image: Reuters

The European Union has asked India to allow it to buy 10 million doses of AstraZeneca's COVID-19 vaccine from Serum Institute of India, a government official told Reuters, the latest sign of growing pressure on Delhi to export more of its production to other countries.

The EU wants the doses from Serum, the world's largest vaccine maker, to offset supply shortfalls from AstraZeneca's European plants and speed up the bloc's vaccine roll-out.

Any quick approval of the EU request is unlikely, however, with India scrambling to expand its own domestic vaccination drive, said the Indian government official, who asked not to be named as the discussions are private.

Follow our LIVE blog for latest updates of the novel coronavirus pandemic

Britain is also pressuring India to export the second half of 10 million doses it had ordered from Serum, the source said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Serum was originally supposed to produce the AstraZeneca vaccine only for low and medium-income countries.

"The EU ambassador wrote a letter, saying, please give us (export) approvals," said the source, adding the letter was sent around two weeks ago.

Serum, AstraZeneca and India's foreign ministry did not respond to requests for comment. A spokeswoman for the EU Commission said the Commission had no immediate comment.

India, however, has said that it is now focused on expanding its own immunisation drive as COVID-19 cases have surged since March.

Its decision to focus on its domestic needs, which came after the government was criticised at home for shipping tens of millions of doses overseas, will also affect the WHO-backed global network for vaccine distribution, known as COVAX. The network aims to secure COVID-19 vaccines primarily for dozens of poorer nations.

Production glitches have slowed vaccinations for the 450 million people in the 27-nation EU. The bloc's per capita immunisation lags that of countries such as Israel, the United Kingdom and the United States, according to the website Our World in Data.

India has so far exported 64 million vaccine doses to 83 countries, and administered the same number of doses at home. Its inoculation drive expanded from Thursday to include everyone above the age of 45, which is expected to raise vaccine demand substantially.

India has reported 12.22 million cases of the coronavirus, the third highest number globally after the United States and Brazil. It has recorded nearly 163,000 deaths from COVID-19.

Follow our full coverage of the coronavirus pandemic here.
Reuters
TAGS: #coronavirus #COVID-19 vaccine #European Union #Health #Serum Institute of India
first published: Apr 1, 2021 07:00 pm